Lyme Disease: Diagnosis and Management in Military Treatment Facilities

LCDR Todd Gleeson MD MPH
Staff Infectious Diseases
National Naval Medical Center
September 5, 2008
Key Issues

• Current status of diagnostic testing for *Borrelia burgdorferi* infection

• Current status of IDSA guidelines

• IDSA versus ILADS guidelines for diagnosis and management of Lyme disease

Infectious Diseases Society of America (IDSA)
The International Lyme and Associated Diseases Society (ILADS)
Reason Presented to DHB

- Provide information on current diagnosis and management of Lyme disease in military medical treatment facilities
Background Information: Diagnosis of Lyme Disease

• Multiple diagnostic methods utilized
  – Clinical diagnosis
  – Two-tier testing
    • Screening Enzyme Linked Immunoassay (ELISA)
    • Confirmatory Western Blot (WB)
  – Polymerase Chain Reaction (PCR)
  – Cerebrospinal fluid testing
Central erythema – 32%

Homogenous – 59%

Central clearing ‘bulls eye’ – only 9%

“classic” EM

118 cases of EM with culture or PCR confirmed *Borrelia burgdorferi* infection EM rashes were:

Ann Intern Med 2002; 136:421
Background Information: Two-Tier Testing

• Screening test
  – Polyvalent ELISA
  – Insensitive in *first two weeks* of infection
  – If positive or indeterminate, confirmatory done

• Confirmatory test
  – Immunoblot of both IgM and IgG
  – CDC criteria used for interpretation
Background Information: Two-Tier Testing

- DOD uses only FDA approved testing
- IGeneX, Inc. in Palo Alto, California
  - Used by Washington, D.C. non-DOD practitioners who claim expertise in Lyme
  - Not FDA-approved
  - Claim “internal validation assays”
  - DOD beneficiaries pay out of pocket
LYME WARS

Let’s tackle the testing

The two tier testing system endorsed by the Centers for Disease Control and Prevention (CDC) has a high specificity (99%) and yields few false positives. But the tests have a uniformly miserable sensitivity (56%)—they miss 88 of every 200 patients with Lyme disease (table). By comparison, AIDS tests have a sensitivity of 99.5%—they miss only one of every 200 AIDS cases. In simple terms, the chance of a patient with Lyme disease being diagnosed using the commercial tests approved by the Food and Drug Administration and sanctioned by the CDC is about getting heads or tails when tossing a coin, and the poor test performance assures that many patients with Lyme disease will go undiagnosed.

Raphael B Stricker past president, International Lyme and Associated Diseases Society, San Francisco, CA 94108, USA
rstricker@usmamed.com

Lorraine Johnson executive director, California Lyme Disease Association, Los Angeles, CA 90068, USA
**Background Information:**

**Two-Tier Testing**

Sensitivity of screening test used at National Naval Medical Center, package insert

<table>
<thead>
<tr>
<th>Stage</th>
<th>Total</th>
<th>Pos</th>
<th>Eqv</th>
<th>Neg</th>
<th>Sensitivity (95% Confidence Intervals)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Localized EM</td>
<td>19</td>
<td>13</td>
<td>0</td>
<td>6</td>
<td>68.4% (47.0 – 85.2)</td>
</tr>
<tr>
<td>Early Convalescent</td>
<td>21</td>
<td>17</td>
<td>0</td>
<td>4</td>
<td>81.0% (61.6 – 93.2)</td>
</tr>
<tr>
<td>Early Neurologic</td>
<td>20</td>
<td>14</td>
<td>0</td>
<td>6</td>
<td>70.0% (49.2 – 86.1)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>60</strong></td>
<td><strong>44</strong></td>
<td>0</td>
<td>16</td>
<td></td>
</tr>
</tbody>
</table>
Background Information: Treatment of Lyme Disease

- Treatment durations well studied
- Military MTF physicians follow IDSA guidelines for Lyme diagnosis and therapy
- ILADS guidelines discussed in Infectious Diseases conferences
The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America
Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review)
Report of the Quality Standards Subcommittee of the American Academy of Neurology

ABSTRACT Objective: To provide evidence-based recommendations on the treatment of nervous system Lyme disease and post-Lyme syndrome. Three questions were addressed: 1) Which antimicrobial agents are effective? 2) Are different regimens preferred for different manifestations of nervous system Lyme disease? 3) What duration of therapy is needed? Methods: The authors analyzed published studies (1983-2003) using a structured review process to classify the evidence related to the questions posed. Results: The panel reviewed 353 abstracts which yielded 112 potentially relevant articles that were reviewed, from which 37 articles were identified that were included in the analysis. Conclusions: There are sufficient data to conclude that, in both adults and children, this nervous system infection responds well to penicillin, ceftriaxone, cefotaxime, and doxycycline (Level B recommendation). Although most studies have used parenteral regimens for neuroborreliosis, several European studies support use of oral doxycycline in adults with meningitis, cranial neuritis, and radiculitis (Level B), reserving parenteral regimens for patients with parenchymal CNS involvement, other severe neurologic symptomatology, or failure to respond to oral regimens. The number of children (≥8 years of age) enrolled in rigorous studies of oral vs parenteral regimens has been smaller, making conclusions less statistically compelling. However, all available data indicate results are comparable to those observed in adults. In contrast, there is no compelling evidence that prolonged treatment with antibiotics has any beneficial effect in post-Lyme syndrome (Level A). NEUROLOGY 2007;69:91-102
Table 3. Recommended therapy for patients with Lyme disease.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Treatment</th>
<th>Duration, days (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tick bite in the United States</td>
<td>Doxycycline, 200 mg in a single dose\textsuperscript{a,b}; (4 mg/kg in children \geq 8 years of age) and/or observation</td>
<td>...</td>
</tr>
<tr>
<td>Erythema migrans</td>
<td>Oral regimen\textsuperscript{c,d}</td>
<td>14 (14–21)\textsuperscript{e}</td>
</tr>
<tr>
<td>Early neurologic disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningitis or radiculopathy</td>
<td>Parenteral regimen\textsuperscript{a,f}</td>
<td>14 (10–28)</td>
</tr>
<tr>
<td>Cranial nerve palsy\textsuperscript{a,g}</td>
<td>Oral regimen\textsuperscript{c}</td>
<td>14 (14–21)</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td>Oral regimen\textsuperscript{a,c,h} or parenteral regimen\textsuperscript{a,c,h}</td>
<td>14 (14–21)</td>
</tr>
<tr>
<td>Borreliotic lymphocytoma</td>
<td>Oral regimen\textsuperscript{c,d}</td>
<td>14 (14–21)</td>
</tr>
<tr>
<td>Late disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritis without neurologic disease</td>
<td>Oral regimen\textsuperscript{c}</td>
<td>28</td>
</tr>
<tr>
<td>Recurrent arthritis after oral regimen</td>
<td>Oral regimen\textsuperscript{a,c} or parenteral regimen\textsuperscript{a,c}</td>
<td>14 (14–28)</td>
</tr>
<tr>
<td>Antibiotic-refractory arthritis\textsuperscript{i}</td>
<td>Symptomatic therapy\textsuperscript{j}</td>
<td>...</td>
</tr>
<tr>
<td>Central or peripheral nervous system disease</td>
<td>Parenteral regimen\textsuperscript{c}</td>
<td>14 (14–28)</td>
</tr>
<tr>
<td>Acrodermatitis chronica atrophicans</td>
<td>Oral regimen\textsuperscript{c}</td>
<td>21 (14–28)</td>
</tr>
<tr>
<td>Post-Lyme disease syndrome</td>
<td>Consider and evaluate other potential causes of symptoms; if none is found, then administer symptomatic therapy\textsuperscript{a}</td>
<td>...</td>
</tr>
</tbody>
</table>
The International Lyme and Associated Diseases Society

Evidence-based guidelines for the management of Lyme disease

The ILADS Working Group
ILADS, P.O. Box 341461
Bethesda, MD 20827-1461, USA
www.ILADS.org

CURRENT CONCEPTS

A Critical Appraisal of “Chronic Lyme Disease”

Henry M. Feder, Jr., M.D., Barbara J.B. Johnson, Ph.D., Susan O’Connell, M.D., Eugene D. Shapiro, M.D., Allen C. Steere, M.D., Gary P. Wormser, M.D., and the Ad Hoc International Lyme Disease Group*
Clinical Cases
Clinical Case #1

- 35 year old male pilot Patuxent River, MD
- Fatigue, difficulty concentrating, headaches three times per week
- Lyme screening test negative Pax River
Clinical Case #1

- Daughter (2 yrs old) was recently hospitalized for Lyme arthritis
- Whole family seeks evaluation at National Integrated Health (Washington, D.C.)
Clinical Case #1

- Family also sees “Lyme specialist” in Connecticut
- NNMC two tier testing negative
- IGeneX Western Blot testing
  - “Indeterminate”
  - National Integrated Health provider recommends prolonged antibiotic therapy
- Patient fills >8 months of amoxicillin and azithromycin at MTF pharmacies
Clinical Case #2

- 41 year old male active duty Army O5
- Tick bite January 2004
  - Empiric doxycycline given for 2 weeks
  - No EM rash present
- Evaluated by Neurology December 2004
  - Lyme serum testing negative
  - Lyme cerebrospinal fluid testing negative
  - Empiric doxycycline for 30 days
Clinical Case #2

- Lyme serologies in 2006 again negative
- Sees civilian provider in Fairfax, VA
  - IGeneX testing positive
  - Recommends prolonged (> 6 months) IV therapy
- WRAMC Infectious Diseases consult
  - July 2007
  - Repeatedly negative testing
  - “Not unreasonable” to give 4 weeks of intravenous ceftriaxone 2 g per day for unexplained neurologic symptoms
Data Presentation

• Up to 25% of patients experience fatigue or muscle aches after antibiotic therapy
• Over time most patients return to normal
• In prospective studies of patients with erythema migrans rash
  – 0.5 to 13.1% experienced subjective symptoms of unknown cause for $\geq 1$ year
  – Whether this prevalence exceeded that of such symptoms in the general population is not known
  – None of these studies included a control group
Data Presentation

- Two placebo-controlled trials in patients with persistent symptoms and a history of Lyme disease
• 78 patients seropositive for \textit{B. burgdorferi}

• 51 patients seronegative

• All patients had antecedent objective signs of Lyme disease (most EM rash)
TWO CONTROLLED TRIALS OF ANTIBIOTIC TREATMENT IN PATIENTS WITH PERSISTENT SYMPTOMS AND A HISTORY OF LYME DISEASE

• Treated with either
  
  – 1 month intravenous ceftriaxone followed by 2 months oral doxycycline

  OR

  – Identical-appearing intravenous and then oral placebos

Assessed at enrollment and 3 months after completion of therapy

Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36)

No significant differences in scores between antibiotic or placebo groups
Policy Recommendations

• Recommend continued use of IDSA guidelines

• Expert panel re-review of guidelines based on lawsuit by Connecticut Attorney General currently underway

• Await outcome of this review by IDSA
Conclusion

• Although sensitivity of screening tests for Lyme disease not 100%
  – MTF physicians utilize multiple clinical and laboratory parameters in evaluation of tickborne disease
  – Military Infectious Diseases physicians see many consults of both Lyme seronegative and seropositive patients

• Military Infectious Diseases specialists available 24 hours a day in all services for expert consultation

• ILADS guidelines expose our patients to potential iatrogenic harm without durable benefit based on best available evidence